Interesting. Any idea who would be the closest competition to RGBP, that has these checkpoint inhibitors in patent lockdown like we do? I’m just thinking, are there any other good alternatives to RGBP in regards to this mRNA science for Big Pharma to consider, or must all paths for this science lead through RGBP and Cornell? Are there other checkpoints besides NR2F6 that would give similar results? I’m feeling like our research is unmatched in this realm and now with Cornell’s vascular endothelial research with tumors it’s a forgone conclusion that we are literally the Diamond in the rough that everyone has been looking for. Seems we were way ahead of the curve in 2016 and overlooked, but the entire field has been turned upside down due to covid and now everyone is flush with cash and scrambling to gain the edge. Lilly makes the most sense here though due to prior connections and the fact that prior jaunts into this wilderness have been unsuccessful. Thoughts?
News 
Market Data 
Discover 
